BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 16243492)

  • 1. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infection in neutropenic cancer patients--etiology, microbiological diagnostics, treatment].
    Durnaá B; Dzierzanowska D
    Wiad Lek; 2006; 59(7-8):506-11. PubMed ID: 17209349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern.
    Butt T; Afzal RK; Ahmad RN; Salman M; Mahmood A; Anwar M
    J Ayub Med Coll Abbottabad; 2004; 16(1):18-22. PubMed ID: 15125174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia.
    Rolston KV
    Clin Infect Dis; 2005 Apr; 40 Suppl 4():S246-52. PubMed ID: 15768330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
    Bow EJ
    Curr Opin Infect Dis; 2011 Dec; 24(6):545-53. PubMed ID: 22001945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis.
    Shenep JL
    NCI Monogr; 1990; (9):117-22. PubMed ID: 2342588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis and treatment of bacterial infections: do we need new strategies?
    Micozzi A; Bucaneve G
    Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial infections in low-risk, febrile neutropenic patients.
    Kamana M; Escalante C; Mullen CA; Frisbee-Hume S; Rolston KV
    Cancer; 2005 Jul; 104(2):422-6. PubMed ID: 15937905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of fever in neutropenic patients with different risks of complications.
    Klastersky J
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S32-7. PubMed ID: 15250018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microbiological isolates in patients with febrile neutropenia and hematological neoplasias].
    Figuera Esparza M; Carballo M; Silva M; Figueredo A; Avilán J
    Rev Esp Quimioter; 2006 Sep; 19(3):247-51. PubMed ID: 17099792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
    Sipsas NV; Bodey GP; Kontoyiannis DP
    Cancer; 2005 Mar; 103(6):1103-13. PubMed ID: 15666328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric therapy for febrile neutropenia: what are the choices?
    Aoun M
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):507-15. PubMed ID: 17547514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments.
    Rolston KV
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S44-8. PubMed ID: 15250020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility.
    Sigurdardottir K; Digranes A; Harthug S; Nesthus I; Tangen JM; Dybdahl B; Meyer P; Hopen G; Løkeland T; Grøttum K; Vie W; Langeland N
    Scand J Infect Dis; 2005; 37(6-7):455-64. PubMed ID: 16012006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia.
    Bal AM; Gould IM
    Int J Antimicrob Agents; 2007 May; 29(5):501-9. PubMed ID: 17346939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
    Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M
    Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of 315neutropenic febrile episodes in a cancer center].
    Dutronc H; Billhot M; Dupon M; Eghbali H; Donamaria C; Dauchy FA; Reiffers J
    Med Mal Infect; 2009 Jun; 39(6):388-93. PubMed ID: 19062208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.